Skip Navigation


Annals of Oncology Advance Access originally published online on April 13, 2005
Annals of Oncology 2005 16(6):934-941; doi:10.1093/annonc/mdi189
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/6/934    most recent
mdi189v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Etienne-Grimaldi, M.-C.
Right arrow Articles by Milano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etienne-Grimaldi, M.-C.
Right arrow Articles by Milano, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients

M.-C. Etienne-Grimaldi1, S. Pereira2, N. Magné3, J.-L. Formento1, M. Francoual1, X. Fontana4, F. Demard5, O. Dassonville5, G. Poissonnet5, J. Santini6, R.-J. Bensadoun7, P. Szepetowski2 and G. Milano1,*

1 Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice; 2 INSERM U491, Faculté de Médecine de la Timone, Marseille, France; 3 Service de Radiothérapie, Institut Jules Bordet, Bruxelles, Belgique; 4 Service de Médecine Nucléaire, Centre Antoine Lacassagne; 5 Service ORL, Centre Antoine Lacassagne; 6 Service ORL du CHU de Nice; 7 Service de radiothérapie, Centre Antoine Lacassagne, Nice, France

* Correspondence to: Dr G. Milano, Oncopharmacology Unit, Centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 2, France. Tel: +33-4-92-03-15-53; Fax: +33-4-93-81-71-31; Email: gerard.milano{at}nice.fnclcc.fr

Background:: Epidermal growth factor receptor (EGFR) overexpression is associated with poor prognosis in head and neck cancer. The first intron of EGFR gene is polymorphic (9–23 CA repeats) and transcription declines when the number of repeats increases.

Patients and methods:: EGFR polymorphism (fluorescent genotyping) and expression (ligand-binding assay) were analyzed in tumors and normal tissues from 112 patients (100 men, 12 women; mean age 60 years).

Results:: The number of CA repeats varied from 15 to 22. Allelic distribution was trimodal (predominance of 16, 20 and 18 CA repeats). EGFR concentrations were significantly higher (P=0.02) in homozygous tumors as compared with heterozygous. Considering homozygous tumors, or classifying genotypes as short/long/intermediary (two alleles <17 versus two alleles ≥17 versus others), no relationship was observed between tumoral EGFR genotype and expression. In the 76 tumors exhibiting at least one 16-CA allele, the length of the remaining allele was inversely correlated to EGFR expression (P=0.047). Tumoral EGFR expression, performance status (WHO criteria) and node involvement were independent predictors of specific survival (P <0.01). Tumoral or normal tissue EGFR genotype did not influence survival.

Conclusions:: Intron 1 EGFR polymorphism may be implicated in the regulation of EGFR expression in head and neck tumors.

Key words: epidermal growth factor receptor, gene polymorphism, head and neck cancer, prognostic markers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. Bergh
Quo Vadis With Targeted Drugs in the 21st Century?
J. Clin. Oncol., January 1, 2009; 27(1): 2 - 5.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Milano, M.-C. Etienne-Grimaldi, L. Dahan, M. Francoual, J.-P. Spano, D. Benchimol, M. Chazal, C. Letoublon, T. Andre, F.-N. Gilly, et al.
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Ann. Onc., December 1, 2008; 19(12): 2033 - 2038.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al.
Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer
J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Hopkins, D. W. Cescon, D. Tse, P. Bradbury, W. Xu, C. Ma, P. Wheatley-Price, J. Waldron, D. Goldstein, F. Meyer, et al.
Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 490 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W.-S. Wang, P.-M. Chen, T.-J. Chiou, J.-H. Liu, J.-K. Lin, T.-C. Lin, H.-S. Wang, and Y. Su
Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma
Clin. Cancer Res., June 15, 2007; 13(12): 3597 - 3604.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S-H. Ou, J. Zell, A Ziogas, and H Anton-Culver
Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology
Ann. Onc., January 1, 2007; 18(1): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Brandt, S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos, and H. Buerger
Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response
Clin. Cancer Res., December 15, 2006; 12(24): 7252 - 7260.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kalyankrishna and J. R. Grandis
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
J. Clin. Oncol., June 10, 2006; 24(17): 2666 - 2672.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Francoual, M.-C. Etienne-Grimaldi, J.-L. Formento, D. Benchimol, A. Bourgeon, M. Chazal, C. Letoublon, T. Andre, N. Gilly, J.-R. Delpero, et al.
EGFR in colorectal cancer: more than a simple receptor
Ann. Onc., June 1, 2006; 17(6): 962 - 967.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.